Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

BACKGROUND: Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selec...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Flaherty, Keith T., Infante, Jeffery R., Daud, Adil, Gonzalez, Rene, Kefford, Richard F., Sosman, Jeffrey, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Ibrahim, Nageatte, Kudchadkar, Ragini, Burris, Howard A., Falchook, Gerald, Algazi, Alain, Lewis, Karl, Long, Georgina V., Puzanov, Igor, Lebowitz, Peter, Singh, Ajay, Little, Shonda, Sun, Peng, Allred, Alicia, Ouellet, Daniele, Kim, Kevin B., Patel, Kiran, Weber, Jeffrey
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549295/
https://ncbi.nlm.nih.gov/pubmed/23020132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1210093
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller